DUBLIN, Oct. 20, 2016 /PRNewswire/ -- Endo
International plc (NASDAQ: ENDP) (TSX: ENL) announced today that
Suketu Upadhyay, Executive Vice
President and Chief Financial Officer, is leaving the Company
effective November 22, 2016 to assume
a senior-level finance position at a global biopharmaceutical
company. Blaise Coleman, Endo's
Senior Vice President of Global Finance Operations, will serve as
Interim Chief Financial Officer. The Company will promptly begin a
search for a permanent Chief Financial Officer.
"We would like to thank Suky for his dedicated service to Endo,
his role in transforming the Company and in building a strong
Finance organization. We wish him the very best in his professional
endeavors and much continued success," said Paul Campanelli, President and Chief Executive
Officer of Endo. "We recently reaffirmed Endo's third quarter and
full year 2016 financial guidance and we remain confident in our
2016 performance. I look forward to working with Suky through his
transition and closely with Blaise as we complete a
product-by-product assessment of our portfolio and further sharpen
Endo's strategy and operational focus."
"My time at Endo has been pivotal for my career and I am very
proud of the best-in-class teams I have built and led for the
Company while contributing to the transformation of Endo since
2013," said Mr. Upadhyay. "I want to thank Paul for the past year
of collaboration and for the confidence he and the Board have put
in my abilities. I am confident that Paul's and the leadership
team's focus on execution will drive success for the Company into
the future."
About Endo International plc
Endo International plc (NASDAQ: ENDP) (TSX: ENL) is a global
specialty pharmaceutical company focused on improving patients'
lives while creating shareholder value. Endo develops,
manufactures, markets and distributes quality branded and generic
pharmaceutical products as well as over-the-counter medications
though its operating companies. Endo has global headquarters in
Dublin, Ireland, and U.S.
headquarters in Malvern, PA. Learn
more at www.endo.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," including, but not limited to, the statements by
Messrs. Campanelli and Upadhyay, as well as Endo's expected,
estimated or anticipated future results. Because forecasts are
inherently estimates that cannot be made with precision, Endo's
performance at times differs materially from its estimates and
targets, and Endo often does not know what the actual results will
be until after the end of the applicable reporting period.
Therefore, Endo will not report or comment on its progress during a
current quarter except through public announcement. Any statement
made by others with respect to progress during a current quarter
cannot be attributed to Endo. All forward-looking statements
in this press release reflect Endo's current analysis of existing
trends and information and represent Endo's judgment only as of the
date of this press release. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Endo's expectations and
projections. Risks and uncertainties include, among other things,
general industry and market conditions; technological advances and
patents attained by competitors; challenges inherent in the
research and development and regulatory processes; challenges
related to product marketing, such as the unpredictability of
market acceptance for new products and/or the acceptance of new
indications for such products; inconsistency of treatment results
among patients; potential difficulties in manufacturing; general
economic conditions; and governmental laws and regulations
affecting domestic and foreign operations. Endo expressly disclaims
any intent or obligation to update these forward-looking statements
except as required by law. Additional information concerning these
and other risk factors can be found in Endo's periodic reports
filed with the U.S. Securities and Exchange Commission and in
Canada on the System for
Electronic Data Analysis and Retrieval ("SEDAR"), including current
reports on Form 8-K, quarterly reports on Form 10-Q and annual
reports on Form 10-K. Additional information about Endo is
available on the World Wide Web at www.endo.com or you can contact
the Endo Investor Relations department by calling (484)
216-0000.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/endo-announces-departure-of-chief-financial-officer-300348747.html
SOURCE Endo International plc